Related Experiment Video
Updated: May 4, 2026

Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion
Published on: June 29, 2012
Rifampin relieves pruritus in children with cholestatic liver disease
H A Cynamon1, J M Andres, R P Iafrate
1Department of Pediatrics, University of Florida, Gainesville.
Rifampin effectively relieved severe itching in children with chronic cholestatic liver disease. This treatment showed sustained effectiveness and no complications, offering a new therapy option.
Area of Science:
- Pediatric Hepatology
- Gastroenterology
- Clinical Pharmacology
Background:
- Chronic cholestatic liver disease in children often causes severe, intractable pruritus.
- Existing therapies, such as cholestyramine, are frequently ineffective for pediatric pruritus.
Purpose of the Study:
- To evaluate the efficacy of rifampin in alleviating pruritus in pediatric patients with chronic cholestasis.
- To assess the safety and sustained effectiveness of rifampin for pruritus management.
Main Methods:
- A 6-week, double-blind, placebo-controlled crossover study was conducted.
- Five pediatric patients with chronic cholestasis and severe pruritus participated.
- Rifampin's effect on pruritus was compared to a placebo.
Main Results:
- Rifampin demonstrated significant effectiveness in relieving pruritus in all five children.
- The therapeutic benefit of rifampin was maintained during a subsequent 6-month treatment period.
- No adverse complications were reported during rifampin administration.
Conclusions:
- Rifampin is a highly effective treatment for severe pruritus associated with chronic cholestasis in children.
- Careful patient selection and frequent monitoring are recommended for this therapy.
- These findings, along with studies in adults, suggest rifampin as a promising therapeutic option.
More Related Videos
04:59Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
Published on: September 27, 2019
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Inhibitors of Viral Protein Synthesis